Hyperion DeFi (NASDAQ:HYPD) Coverage Initiated at Chardan Capital

Analysts at Chardan Capital began coverage on shares of Hyperion DeFi (NASDAQ:HYPD) in a report issued on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating on the stock.

Other equities research analysts have also issued reports about the company. Wall Street Zen upgraded Hyperion DeFi from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Hyperion DeFi in a research note on Wednesday, October 8th. Finally, Cantor Fitzgerald began coverage on Hyperion DeFi in a report on Tuesday, December 16th. They set an “overweight” rating and a $4.00 target price on the stock. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $4.58.

Hyperion DeFi Price Performance

Shares of HYPD stock opened at $4.02 on Wednesday. The stock’s fifty day simple moving average is $5.02 and its 200 day simple moving average is $7.54. Hyperion DeFi has a one year low of $0.85 and a one year high of $17.99. The firm has a market cap of $32.84 million, a price-to-earnings ratio of -1.00 and a beta of 2.80. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.25 and a quick ratio of 2.25.

Hyperion DeFi (NASDAQ:HYPD) last issued its quarterly earnings data on Friday, November 14th. The company reported $0.05 earnings per share for the quarter. The firm had revenue of $0.36 million for the quarter. Hyperion DeFi had a negative net margin of 62,238.41% and a negative return on equity of 119.59%. On average, analysts expect that Hyperion DeFi will post -41.6 earnings per share for the current fiscal year.

Insider Transactions at Hyperion DeFi

In other Hyperion DeFi news, Director Michael S. Geltzeiler acquired 30,000 shares of Hyperion DeFi stock in a transaction on Wednesday, December 17th. The shares were purchased at an average cost of $3.01 per share, with a total value of $90,300.00. Following the completion of the purchase, the director owned 88,015 shares in the company, valued at $264,925.15. The trade was a 51.71% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ellen R. Strahlman bought 19,702 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were acquired at an average price of $3.14 per share, with a total value of $61,864.28. Following the transaction, the director directly owned 95,150 shares in the company, valued at approximately $298,771. The trade was a 26.11% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 130,374 shares of company stock worth $398,043 in the last quarter. 10.86% of the stock is owned by company insiders.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.